C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
195/1.105
C12N 5/02 (2006.01) A61K 39/395 (2006.01) C07K 16/00 (2006.01) C12N 5/16 (2006.01) C12N 15/00 (2006.01)
Patent
CA 1193562
ABSTRACT OF THE DISCLOSURE Human monoclonal antibody compositions, human- human monoclonal hybridoma cells, human non-viral trans- formed particularly non-Epstein-Barr virus transformed, neoplastic lymphoid cells, human antibody genes and their uses. Human neoplastic cells are developed for fusing with immunized lymphoid cells to provide stable human-human hybridoma strains producing complete monoclonal antibodies for a predefined antigen. From a myeloma cell line, rapidly growing 8-azaguanine resistant HAT sensitive cells are selected. The selected myeloma cells are crossed with immunized lymphoid cells and the resulting cell mixture grown under controlled selective conditions. Lymphoma cells may be substituted for the myeloma cells. After expansion of the desired hybridoma cells, the monoclonal antibodies may be harvested. The hybridomas serve as a source for messenger RNA for light and heavy chains which may be used for production of light and heavy chain immunoglobulin proteins through hybrid DNA techniques. U-266-AR1 cell line has been deposited at Cell Distribution Center, The Salk Institute on July 17, 1980, and the A.T.C.C. on September 11, 1980.
381916
Kaplan Henry S.
Olsson Lennart
Board Of Trustees Of Leland Stanford Jr. University
Fetherstonhaugh & Co.
LandOfFree
Human hybridomas, precursors and products does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human hybridomas, precursors and products, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human hybridomas, precursors and products will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1265617